WELL Health Technologies Corp. (WELL.TO)
| Previous close | 3.5800 |
| Open | 3.7100 |
| Bid | 3.9400 x N/A |
| Ask | 3.9500 x N/A |
| Day's range | 3.6800 - 3.9800 |
| 52-week range | 3.4100 - 5.5500 |
| Volume | |
| Avg. volume | 943,436 |
| Market cap | 973.21M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | ∞ |
| EPS (TTM) | 0.0000 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.39 |
PR NewswireWELL Health Reports Record Quarterly Revenue and Record Net Income for a first quarter in Q1-2024 and Increases Both Revenue and Adjusted EBITDA Guidance for 2024
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce its interim consolidated financial results for the quarter ended March 31, 2024.
PR NewswireWELL Health to Announce First Quarter 2024 Financial Results on May 8, 2024
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal First Quarter 2024 financial results for the period ended March 31, 2024, on Wednesday, May 8, 2024. The Company will hold a conference call and simultaneous webcast to discuss its res
GlobeNewswireWELL Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI
WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support (“WAIDS”), which now features advanced chronic disease screening for diseases like chronic kidney disease, hypertension, and diabetes, enabling patient risk stratification.The updated WAIDS tool identifies over one hundred diseases and delivers actionable clinical insights at the point of care, contributing to the management of chronic disease-related costs in Canada, which are estimated to be approximately $190
